BSE filing, NSE: NOVARTIND. Summary written from the filing by ALFA Finder's alert engine.
Novartis India Ltd: key numbers
- Share price
- ₹1,714.35
- Market cap
- ₹4,233 Cr
- Revenue (annual)
- ₹354.3 Cr
- Net profit (annual)
- ₹93.18 Cr
- P/E (TTM)
- -1060.9×Sector 42.0×
- Promoter holding
- 70.68%+0.00% QoQ
- FII holding
- 1.21%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Novartis India Ltd
All →Evonile Pharma Fund Raise of ₹900 Cr
Evonile Pharma's board approved a partly paid rights issue of up to Rs 900 Crore. A committee will set the issue price, record date and entitlement.
- Value
- ₹900.0 Cr
Evonile Pharma Capital Structure Change
Evonile Pharma's Rights Issue Committee fixed November 11, 2026 as record date for a partly paid rights issue of 1,02,87,832 shares at Rs.860 each. Issue size is Rs.8,847.54 Million, with issue opening November 19, 2026.
- Value
- ₹884.8 Cr
- Execution
- Issue opening 19 Nov 2026 to closing 3 Dec 2026; listing on or about 9 Dec 2026
Evonile Pharma Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue ₹56.1 cr (-38% YoY) and PAT loss ₹77.5 cr, including ₹68 cr exceptional items. H1 revenue ₹159.9 cr (-10%). Transitioning to an independent branded pharma model; Minipress XL acquired.
Evonile Pharma Results Update
Evonile Pharma reported Q2 FY27 revenue of ₹56.1 crore and an EBITDA loss of ₹31.8 crore. H1 FY27 profit after tax was a loss of ₹45.3 crore.
Evonile Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue fell 38% YoY to ₹56.1 cr, with a ₹77.5 cr net loss including ₹68 cr exceptional items. Transition from single-customer model to independent distribution continues.
Evonile Pharma Q2 FY27 Results: Net Loss of ₹77.5 Cr
Evonile Pharma posted a ₹775.4 million quarterly loss for September 2026 versus profit a quarter earlier. Exceptional items of ₹682.6 million drove the half-year pre-tax loss.
- Key figure
- Net loss ₹77.5 Cr
Other board meeting outcome announcements
All →CMX Holdings Board Meeting Outcome
Riwind Green Energy (formerly CMX Holdings) board approved altering its MOA main objects into six consolidated objects and a postal ballot notice. The change refocuses the company on solar, EPC, battery storage and renewable data-centre businesses.
Sahajanand Medical Technologies Board Meeting Outcome
Sahajanand Medical Technologies' board appointed M/s Amit Jaste & Associates as Secretarial Auditor for FY 2026-27 to FY 2030-31. The appointment is subject to shareholder approval.
- Execution
- FY 2026-27 to FY 2030-31, five consecutive financial years, subject to shareholder approval
Gretex Corporate Services Board Meeting Outcome
Gretex Corporate Services re-appointed Arvind Harlalka, Alok Harlalka and Rajiv Kumar Agarwal as directors after a board meeting. Terms are 60 months, effective from April 2027 and May 2027.
- Execution
- 60 months
Rajasthan Cylinders & Containers Board Meeting Outcome
Rajasthan Cylinders' board approved unaudited results for the quarter and half year ended September 30, 2026. The filing contains no financial figures.
Panasonic Carbon India Co Board Meeting Outcome
Panasonic Carbon's board recommended Brahmayya & Co. as statutory auditors for five years, from the 45th AGM in 2027. Standalone unaudited Q2 results were also approved.
- Execution
- Five years, from the conclusion of the 45th AGM (2027) to the conclusion of the 50th AGM (2032)
Safari Industries (India) Board Meeting Outcome
Safari Industries (India) Limited has approved a revised Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information. The amendment ensures compliance with SEBI Regulations.